Future studies to address this clinical problem are needed to define optimum treatment regimes, the sensitivity of the CSC population to specific COX-2 inhibitors, and to determine different pharmacokinetics and pharmacodynamics associated with chemotherapy, as some drugs may be better or poorer induces of tumour repopulation. The gene discussed is PTGS2; the disease is neoplasm.